Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Liver cancer-related gene CYP2E1 expression in HBV transgenic mice with acute liver injury

verfasst von: Chun Zhang, Qin Wei, Tao Jiang, Xi Shou, Zhi-Qiang Li, Hao Wen

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The objective of this research was to study the CYP2E1 gene expression in carbon tetrachloride (CCl4)-induced acute liver injury in hepatitis B virus (HBV) transgenic mice. Twenty-four HBV (−) and 24 HBV (+) transgenic mice aged 8 to 10 weeks were selected for the present study. Intraperitoneal injection of 1.0 μL/g of CCl4 (1:4 dissolved in olive oil) to mice was performed to induce acute liver injury model. Eight normal clean-grade C57BL/6 mice were taken as the control group. The control group received saline intraperitoneally. The mice in each group were killed 3, 6, 12, 24, 48, and 72 h after injection. The liver tissue samples of mice were collected. The liver histological changes at different time points in each group were observed under light microscope. The quantitative PCR methods were utilized to measure the relative mRNA levels of CYP2E1 gene in liver tissues. Immunohistochemistry and Western blot techniques were used to observe tissue expression levels of CYP2E1 in each group. Compared with that of the control group, mRNA and protein expression levels of CYP2E1 significantly increased both in the HBV (−) group and in the HBV (+) group after the CCl4 induced the acute liver injury, and it reached the peak at 72 h after the CCl4 injection. Compared with the HBV (−) group, the mice in the HBV (+) group had severe liver damage and significantly increased CYP2E1 gene and protein expression levels. In the CCl4-induced acute liver injury of HBV transgenic mice, the CYP2E1 gene expression significantly increased. The results provided evidence for the HBV-induced liver damage and liver cancer pathogenesis.
Literatur
1.
Zurück zum Zitat Wong GL, Wong VW. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol. 2013;19:6515–22.PubMedCentralPubMedCrossRef Wong GL, Wong VW. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol. 2013;19:6515–22.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Liu Y, Jiang L, Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncol Lett. 2013;6(3):821–8.PubMedCentralPubMed Liu Y, Jiang L, Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncol Lett. 2013;6(3):821–8.PubMedCentralPubMed
3.
Zurück zum Zitat Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, et al. Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients. Liver Int. 2013. doi:10.1111/liv.12347. Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, et al. Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients. Liver Int. 2013. doi:10.​1111/​liv.​12347.
4.
Zurück zum Zitat Han Y, Pu R, Han X, Zhao J, Li W, Yin J, et al. Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk. Liver Int. 2013. doi:10.1111/liv.12313. Han Y, Pu R, Han X, Zhao J, Li W, Yin J, et al. Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk. Liver Int. 2013. doi:10.​1111/​liv.​12313.
5.
Zurück zum Zitat Zhang H, Li H, Yang Y, Li S, Ren H, Zhang D, et al. Differential regulation of host genes including hepatic fatty acid synthase in HBV-transgenic mice. J Proteome Res. 2013;12:2967–79.PubMedCrossRef Zhang H, Li H, Yang Y, Li S, Ren H, Zhang D, et al. Differential regulation of host genes including hepatic fatty acid synthase in HBV-transgenic mice. J Proteome Res. 2013;12:2967–79.PubMedCrossRef
6.
Zurück zum Zitat Buchmann P, Dembek C, Kuklick L, Jäger C, Tedjokusumo R, von Freyend MJ, et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine. 2013;31:1197–203.PubMedCrossRef Buchmann P, Dembek C, Kuklick L, Jäger C, Tedjokusumo R, von Freyend MJ, et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine. 2013;31:1197–203.PubMedCrossRef
7.
Zurück zum Zitat Farag MM, Tedjokusumo R, Flechtenmacher C, Asen T, Stremmel W, Müller M, et al. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine. 2012;30:6034–9.PubMedCrossRef Farag MM, Tedjokusumo R, Flechtenmacher C, Asen T, Stremmel W, Müller M, et al. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine. 2012;30:6034–9.PubMedCrossRef
8.
Zurück zum Zitat Jiang W. Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice. Vaccine. 2012;30:758–66.PubMedCrossRef Jiang W. Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice. Vaccine. 2012;30:758–66.PubMedCrossRef
9.
Zurück zum Zitat Ren W, Qi X, Yang Z, Han G, Fan D. Prevalence and risk factors of hepatocellular carcinoma in Budd–Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol. 2013;25:830–41.PubMedCrossRef Ren W, Qi X, Yang Z, Han G, Fan D. Prevalence and risk factors of hepatocellular carcinoma in Budd–Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol. 2013;25:830–41.PubMedCrossRef
10.
Zurück zum Zitat Li G, Zheng Z. Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumour Biol. 2013;34:1589–94.PubMedCrossRef Li G, Zheng Z. Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumour Biol. 2013;34:1589–94.PubMedCrossRef
11.
Zurück zum Zitat Wu X, Xin Z, Zhang W, Wu J, Chen K, Wang H, et al. Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity. Int J Cancer. 2013;133:1085–93. doi:10.1002/ijc.28109.PubMedCrossRef Wu X, Xin Z, Zhang W, Wu J, Chen K, Wang H, et al. Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity. Int J Cancer. 2013;133:1085–93. doi:10.​1002/​ijc.​28109.PubMedCrossRef
12.
Zurück zum Zitat Deng B, Liu F, Wei Y, Luo L, Chen X, Yan L, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population. Tumour Biol. 2013;34(1):293–9.PubMedCrossRef Deng B, Liu F, Wei Y, Luo L, Chen X, Yan L, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population. Tumour Biol. 2013;34(1):293–9.PubMedCrossRef
13.
Zurück zum Zitat Wang L, Huang J, Jiang M, Lin H, Qi L, Diao H. Activated PTHLH coupling feedback phosphoinositide to G-protein receptor signal-induced cell adhesion network in human hepatocellular carcinoma by systems-theoretic analysis. ScientificWorldJournal. 2012;2012:428979.PubMedCentralPubMed Wang L, Huang J, Jiang M, Lin H, Qi L, Diao H. Activated PTHLH coupling feedback phosphoinositide to G-protein receptor signal-induced cell adhesion network in human hepatocellular carcinoma by systems-theoretic analysis. ScientificWorldJournal. 2012;2012:428979.PubMedCentralPubMed
14.
Zurück zum Zitat Arzumanyan A, Sambandam V, Clayton MM, Choi SS, Xie G, Diehl AM, et al. Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res. 2012;72:5912–20.PubMedCentralPubMedCrossRef Arzumanyan A, Sambandam V, Clayton MM, Choi SS, Xie G, Diehl AM, et al. Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res. 2012;72:5912–20.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Liu H, Xu L, He H, Zhu Y, Liu J, Wang S, et al. Hepatitis B virus X protein promotes hepatoma cell invasion and metastasis by stabilizing Snail protein. Cancer Sci. 2012;103:2072–81.PubMedCrossRef Liu H, Xu L, He H, Zhu Y, Liu J, Wang S, et al. Hepatitis B virus X protein promotes hepatoma cell invasion and metastasis by stabilizing Snail protein. Cancer Sci. 2012;103:2072–81.PubMedCrossRef
16.
Zurück zum Zitat Bose S, Tripathi DM, Sukriti SP, Kazim SN, Sarin SK. Genetic polymorphisms of CYP2E1 and DNA repair genes HOGG1 and XRCC1: association with hepatitis B related advanced liver disease and cancer. Gene. 2013;519(2):231–7.PubMedCrossRef Bose S, Tripathi DM, Sukriti SP, Kazim SN, Sarin SK. Genetic polymorphisms of CYP2E1 and DNA repair genes HOGG1 and XRCC1: association with hepatitis B related advanced liver disease and cancer. Gene. 2013;519(2):231–7.PubMedCrossRef
17.
Zurück zum Zitat Tian Z, Li YL, Zhao L, Zhang CL. CYP2E1 RsaI/PstI polymorphism and liver cancer risk among east Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:4915–21.PubMedCrossRef Tian Z, Li YL, Zhao L, Zhang CL. CYP2E1 RsaI/PstI polymorphism and liver cancer risk among east Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:4915–21.PubMedCrossRef
18.
Zurück zum Zitat Catanzaro I, Naselli F, Saverini M, Giacalone A, Montalto G, Caradonna F. Cytochrome P450 2E1 variable number tandem repeat polymorphisms and health risks: a genotype-phenotype study in cancers associated with drinking and/or smoking. Mol Med Rep. 2012;6:416–20.PubMed Catanzaro I, Naselli F, Saverini M, Giacalone A, Montalto G, Caradonna F. Cytochrome P450 2E1 variable number tandem repeat polymorphisms and health risks: a genotype-phenotype study in cancers associated with drinking and/or smoking. Mol Med Rep. 2012;6:416–20.PubMed
19.
Zurück zum Zitat Liu C, Wang H, Pan C, Shen J, Liang Y. CYP2E1 PstI/RsaI polymorphism and interaction with alcohol consumption in hepatocellular carcinoma susceptibility: evidence from 1,661 cases and 2,317 controls. Tumour Biol. 2012;33(4):979–84.PubMedCrossRef Liu C, Wang H, Pan C, Shen J, Liang Y. CYP2E1 PstI/RsaI polymorphism and interaction with alcohol consumption in hepatocellular carcinoma susceptibility: evidence from 1,661 cases and 2,317 controls. Tumour Biol. 2012;33(4):979–84.PubMedCrossRef
20.
Zurück zum Zitat Ye X, Peng T, Liu T, Su Z, Xiao K, Shang L, et al. Association between aldehyde dehydrogenase-2/cytochrome P450 2E1 genetic polymorphism and habit of alcohol drinking and the susceptibility of hepatocellular carcinoma. Wei Sheng Yan Jiu. 2010;39:42–5.PubMed Ye X, Peng T, Liu T, Su Z, Xiao K, Shang L, et al. Association between aldehyde dehydrogenase-2/cytochrome P450 2E1 genetic polymorphism and habit of alcohol drinking and the susceptibility of hepatocellular carcinoma. Wei Sheng Yan Jiu. 2010;39:42–5.PubMed
21.
Zurück zum Zitat Barone M, Spano D, D’Apolito M, Centra M, Lasalandra C, Capasso M, et al. Iolascon A Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. Mol Med. 2006;12:115–23.PubMedCentralPubMedCrossRef Barone M, Spano D, D’Apolito M, Centra M, Lasalandra C, Capasso M, et al. Iolascon A Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. Mol Med. 2006;12:115–23.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Ghebranious N, Sell S. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology. 1998;27(2):383–91.PubMedCrossRef Ghebranious N, Sell S. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology. 1998;27(2):383–91.PubMedCrossRef
24.
Zurück zum Zitat Wang Y, Millonig G, Nair J, Patsenker E, Stickel F, Mueller S, et al. Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. Hepatology. 2009;50:453–61.PubMedCrossRef Wang Y, Millonig G, Nair J, Patsenker E, Stickel F, Mueller S, et al. Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. Hepatology. 2009;50:453–61.PubMedCrossRef
25.
Zurück zum Zitat Man XB, Tang L, Qiu XH, Yang LQ, Cao HF, Wu MC, et al. Expression of cytochrome P4502E1 gene in hepatocellular carcinoma. World J Gastroenterol. 2004;10(11):1565–8.PubMed Man XB, Tang L, Qiu XH, Yang LQ, Cao HF, Wu MC, et al. Expression of cytochrome P4502E1 gene in hepatocellular carcinoma. World J Gastroenterol. 2004;10(11):1565–8.PubMed
26.
Zurück zum Zitat You X, Liu F, Zhang T, Li Y, Ye L, Zhang X. Hepatitis B virus X protein upregulates oncogene Rab18 to result in the dysregulation of lipogenesis and proliferation of hepatoma cells. Carcinogenesis. 2013;34(7):1644–52.PubMedCrossRef You X, Liu F, Zhang T, Li Y, Ye L, Zhang X. Hepatitis B virus X protein upregulates oncogene Rab18 to result in the dysregulation of lipogenesis and proliferation of hepatoma cells. Carcinogenesis. 2013;34(7):1644–52.PubMedCrossRef
27.
Zurück zum Zitat Lim W, Kwon SH, Cho H, Kim S, Lee S, Ryu WS, et al. HBx targeting to mitochondria and ROS generation are necessary but insufficient for HBV-induced cyclooxygenase-2 expression. J Mol Med (Berl). 2010;88(4):359–69.CrossRef Lim W, Kwon SH, Cho H, Kim S, Lee S, Ryu WS, et al. HBx targeting to mitochondria and ROS generation are necessary but insufficient for HBV-induced cyclooxygenase-2 expression. J Mol Med (Berl). 2010;88(4):359–69.CrossRef
28.
Zurück zum Zitat Cheng AS, Yu J, Lai PB, Chan HL, Sung JJ. COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. Biochem Biophys Res Commun. 2008;374(2):175–80.PubMedCrossRef Cheng AS, Yu J, Lai PB, Chan HL, Sung JJ. COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. Biochem Biophys Res Commun. 2008;374(2):175–80.PubMedCrossRef
Metadaten
Titel
Liver cancer-related gene CYP2E1 expression in HBV transgenic mice with acute liver injury
verfasst von
Chun Zhang
Qin Wei
Tao Jiang
Xi Shou
Zhi-Qiang Li
Hao Wen
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1486-4

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.